Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Recruiting · NCT07513948 · Registry updated 2026-04-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, acquired thrombotic thrombocytopenic purpura, blood coagulation disease, blood platelet disease, hematologic disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura | Recruiting | Not stated | 2026-04-14 | NCT07513948 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 90 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Angelo Bianchi Bonomi Hemophilia and Thrombosis Center | Milan | Italy | 1 |